TEKAMLO SUMMARY
Tekamlo is a single tablet of aliskiren hemifumarate (an orally active, nonpeptide, potent direct renin inhibitor) and amlodipine besylate (a dihydropyridine calcium channel blocker).
Tekamlo (ALISKIREN/AMLODIPINE) is indicated for the following:
Tekamlo is a combination of aliskiren, a renin inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, indicated for the treatment of hypertension:
- As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals. (1)
- In patients not adequately controlled with monotherapy.
- As a substitute for its titrated components.
|
NEWS HIGHLIGHTSMedia Articles Related to Tekamlo (Aliskiren / Amlodipine)
Pulmonary Hypertension
Source: MedicineNet Chronic Obstructive Pulmonary Disease (COPD) Specialty [2013.11.25]
Title: Pulmonary Hypertension
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 11/25/2013 12:00:00 AM
Increased risk of alcohol-related hypertension in individuals who flush after drinking
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today [2013.11.21]
Excessive drinking is a known risk factor for hypertension. Drinking that results in facial flushing indicates high sensitivity or even intolerance to alcohol. A study of the relationship between drinking and these two conditions has found that drinking-related hypertension has a lower threshold value and higher risk in flushers than in non-flushers.
Some allergy suffers with hypertension may be at increased risk for severe reaction
Source: Allergy News From Medical News Today [2013.11.12]
Oral allergy syndrome sufferers that take high blood pressure medications may experience extreme facial swelling and difficulty breathing the next time they bite into a juicy apple.
In low-income urban neighborhoods the rates of diabetes, hypertension, heart disease and stroke are much higher
Source: Hypertension News From Medical News Today [2013.11.07]
There is more to the cost of living in a food desert than higher prices for the few fruits and vegetables sold nearby, according to a study by an Indiana University-Purdue University Indianapolis researcher and the Marion County Public Health Department.
Further positive Opsumit (macitentan) data in pulmonary arterial hypertension presented at CHEST 2013
Source: Hypertension News From Medical News Today [2013.10.31]
Actelion (SIX: ATLN) has announced that following the recent FDA approval and positive CHMP opinion for macitentan (Opsumit®) in pulmonary arterial hypertension (PAH), further positive data on the efficacy of macitentan from the SERAPHIN study were presented at CHEST 2013 in Chicago, USA (26-31 October 2013).
Published Studies Related to Tekamlo (Aliskiren / Amlodipine)
Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover study. [2011.06]
CONCLUSIONS: Direct renin inhibition by aliskiren partially counteracts the microcirculatory changes responsible for calcium-channel-induced edema formation, possibly through preferential vasodilation of venous capacitance vessels.
Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension. [2011.03]
Minority patients with hypertension generally require combination therapy to reach blood pressure (BP) goals. We examined the BP-lowering efficacy and safety of combination aliskiren/amlodipine therapy in self-identified minority patients in the United States with stage 2 hypertension and the impact of adding hydrochlorothiazide (HCTZ) to this combination...
Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension and obesity or metabolic syndrome. [2011.11]
The renin-angiotensin system (RAS) is a common link between hypertension and comorbidities of obesity and metabolic syndrome (MetS). We evaluated the antihypertensive efficacy and safety of the combination direct renin inhibitor, aliskiren, with amlodipine versus amlodipine alone in self-identified African Americans with stage 2 hypertension in a subgroup of patients with obesity or MetS participating in the Aliskiren Amlodipine Combination in African AmEricans with Stage 2 HypertenSion (AACESS) trial.
Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension. [2011.08]
Initial multiple drug therapy for hypertension achieves greater and quicker reductions and higher blood pressure (BP) control rates than monotherapy. This 8-week, prospective, multicenter, randomized, double-blind study compared the efficacy and safety of the initial combination of aliskiren/amlodipine with amlodipine monotherapy in African Americans with stage 2 hypertension...
Comparative efficacy and safety of combination aliskiren/amlodipine and
amlodipine monotherapy in African Americans with stage 2 hypertension. [2011]
Initial multiple drug therapy for hypertension achieves greater and quicker
reductions and higher blood pressure (BP) control rates than monotherapy. This
8-week, prospective, multicenter, randomized, double-blind study compared the
efficacy and safety of the initial combination of aliskiren/amlodipine with
amlodipine monotherapy in African Americans with stage 2 hypertension...
Clinical Trials Related to Tekamlo (Aliskiren / Amlodipine)
Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension [Recruiting]
Part 1 investigated aliskiren, amlodipine and angiotensin II levels in interstitial fluid of
fat and skeletal muscle; aliskiren concentration, angiotensin II levels, and renin activity
and concentration in fat and skeletal muscle tissues; aliskiren and amlodipine
concentrations, angiotensin II levels, and renin activity and concentrations in plasma.
Part 2 investigates the potential for aliskiren to modulate renin-angiotensin-aldosterone
system (RAAS) activity, and lipid/carbohydrate metabolism in adipose and skeletal muscle
tissue in obese patients with hypertension in comparison to amlodipine.
A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People [Recruiting]
This study will provide new information regarding the role of aliskiren (with or without
additional therapy with a diuretic or a CCB) in elderly individuals (≥ 65 years) with SBP
130 to 159 mmHg, in preventing major CV events and on global measures of physical, executive
and cognitive function.
Reports of Suspected Tekamlo (Aliskiren / Amlodipine) Side Effects
Diabetes Mellitus (6),
Osteoporosis (6),
Poor Quality Sleep (6),
Blood Uric Acid Increased (6),
Vasodilatation (6),
Breast Cancer (6),
Hypoaesthesia (6),
Alopecia (6),
Hypothyroidism (6),
Oedema Peripheral (3), more >>
|
